3X4 Genetics Test + Blueprint Report

Methylation is a fundamental biochemical process that regulates gene expression, neurotransmitter metabolism, and homocysteine recycling. Key enzymes include methylenetetrahydrofolate reductase (MTHFR), which converts folate to its active form; methionine synthase (MTR) and its reductase (MTRR), which regenerate methionine from homocysteine; and catechol-O-methyltransferase (COMT), which inactivates catecholamines. Genetic variants in these enzymes can alter their efficiency, influencing nutrient requirements, detoxification capacity, and responses to environmental stressors.

Variants in methylation genes are common and often clinically silent, but in some contexts they may inform targeted folate supplementation (5-methyltetrahydrofolate for MTHFR variants), modulate cardiovascular risk in the presence of elevated homocysteine, and guide nutritional and lifestyle strategies in functional and integrative practice. These findings are not diagnostic of disease and should be integrated with biochemical markers.

Phase I detoxification is mediated by cytochrome P450 enzymes that add reactive groups to xenobiotics, while phase II conjugation enzymes — including glutathione S-transferases (GST) and N-acetyltransferases (NAT) — render intermediates water-soluble for excretion. Genetic polymorphisms can create rapid or slow metaboliser phenotypes, altering the clearance of environmental toxins, pharmaceuticals, and endogenous compounds such as oestrogens.

Detoxification variants influence individual responses to environmental exposures, caffeine metabolism, breast cancer risk modulation (particularly CYP1B1 in oestrogen metabolism), and may guide personalised recommendations around cruciferous vegetable intake, antioxidant support, and exposure minimisation. Functional interpretation remains exploratory and is not a substitute for standard toxicology or pharmacogenomic testing.

Cytokines such as interleukin-6, tumour necrosis factor alpha, and interleukin-1 beta mediate acute and chronic inflammation, while interleukin-10 exerts anti-inflammatory effects. Promoter and coding variants can shift the balance toward higher or lower cytokine production in response to infection, injury, or metabolic stress, influencing susceptibility to chronic inflammatory conditions.

Genetic predisposition to heightened inflammatory responses may inform strategies to mitigate chronic low-grade inflammation through diet (anti-inflammatory foods, omega-3 fatty acids), lifestyle (exercise, sleep, stress management), and targeted nutraceuticals. These findings do not predict or diagnose autoimmune or inflammatory disease and should be integrated with inflammatory biomarkers such as high-sensitivity CRP.

Apolipoprotein E (APOE) isoforms influence lipid clearance and Alzheimer risk; fat mass and obesity-associated protein (FTO) and transcription factor 7-like 2 (TCF7L2) variants modulate adiposity, insulin secretion, and type 2 diabetes susceptibility; peroxisome proliferator-activated receptor gamma (PPARG) regulates adipocyte differentiation and insulin sensitivity. These variants interact extensively with diet and physical activity.

Cardiometabolic variants can guide macronutrient distribution (saturated fat responsiveness in APOE4 carriers), inform diabetes and cardiovascular risk stratification, and tailor exercise and dietary interventions. Findings are probabilistic and should be integrated with lipid panels, glucose tolerance, and anthropometric measures rather than used in isolation.

The vitamin D receptor (VDR) mediates genomic effects of 1,25-dihydroxyvitamin D; vitamin D binding protein (encoded by GC) influences circulating and tissue 25-hydroxyvitamin D; FUT2 secretor status affects gut microbiome composition and B12 absorption; beta-carotene 15,15'-monooxygenase (BCMO1) converts plant carotenoids to retinol. Genetic variation in these pathways alters nutrient bioavailability and requirements.

Variants inform targeted supplementation strategies (higher-dose vitamin D for certain VDR or GC genotypes, preformed vitamin A rather than carotenes for poor BCMO1 converters) and may explain discordance between dietary intake and circulating nutrient levels. Direct measurement of nutrient status remains the gold standard for dosing decisions.

Superoxide dismutase 2 (SOD2) converts mitochondrial superoxide to hydrogen peroxide, glutathione peroxidase (GPX1) reduces peroxides using glutathione, and catalase (CAT) degrades hydrogen peroxide to water. Polymorphisms can reduce enzyme efficiency, increasing susceptibility to oxidative damage under conditions of metabolic or environmental stress.

Variants in antioxidant enzymes may guide the use of dietary antioxidants, support for glutathione synthesis (N-acetylcysteine, glycine, selenium), and mitigation of oxidative triggers (smoking, pollution, high-intensity exercise). These are functional insights, not diagnostic markers, and should be integrated with oxidative stress biomarkers such as 8-hydroxy-2'-deoxyguanosine or lipid peroxides where available.